Foghorn Therapeutics Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Foghorn Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Foghorn Therapeutics Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$26.6M, a 16.9% increase year-over-year.
  • Foghorn Therapeutics Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$97.4M, a 22.4% increase year-over-year.
  • Foghorn Therapeutics Inc. annual Operating Income (Loss) for 2023 was -$108M, a 7.88% increase from 2022.
  • Foghorn Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$117M, a 16.3% decline from 2021.
  • Foghorn Therapeutics Inc. annual Operating Income (Loss) for 2021 was -$101M, a 47% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$108M +$9.23M +7.88% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-07
2022 -$117M -$16.4M -16.3% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-07
2021 -$101M -$32.2M -47% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-09
2020 -$68.5M -$17.4M -34.2% Jan 1, 2020 Dec 31, 2020 10-K/A 2022-08-09
2019 -$51.1M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.